Dendritic cell therapy for pancreatic cancer in Germany

With an annual increase in incidence of 0.5-1.0%, pancreatic cancer is rapidly approaching the status of the second leading cause of cancer mortality by 2030. Such dynamics make the issue of finding effective treatment methods critically important for modern oncology [1]. Pancreatic cancer is also infamous for its resistance to conventional cancer treatment, fast development, and early metastasis. 

Nevertheless, there is some light at the end of the tunnel with the recent development of dendritic cell-based immunotherapy against pancreatic cancer, particularly in countries such as Germany, where modern clinics are now using the immunotherapy method. An important indicator of treatment success is the achievement of a recurrence-free survival rate of more than 60% within two years, which is exactly what doctors define as significant clinical progress [2]. Through the strength of the immune system, these new vaccines for pancreatic cancer help activate immune cells (especially T-cells), engaging them to specifically identify and kill pancreatic cancer cells.

Dendritic cell therapy is turning out to be an attractive solution for pancreatic adenocarcinoma as clinical experience increases, promising to offer new insights for patients with pancreatic cancer and to redefine the possibilities of treating pancreatic cancer through the activation of natural immune responses.

Understanding Pancreatic Cancer and Why It Is Difficult to Treat

Scientists refer to pancreatic ductal adenocarcinoma (PDAC) as the most common type of pancreatic cancer that constitutes over 90% of all tumors of this organ [3]. Pancreatic adenocarcinoma has been known for causing quick progression, early spreading, and insidious onset of the disease, and this is the reason why most patients with pancreatic cancer are diagnosed in very advanced stages when only innovative therapy can be administered [4, 5].

Pancreatic cancer is not the easiest malignancy to treat due to several reasons:

• Massive stroma: The fibrotic tissue surrounding pancreatic cancer cells forms a mechanical barrier that blocks the drug delivery process.
• Immunosuppressive microenvironment: Pancreatic ductal adenocarcinoma, in contrast to certain other malignancies, induces the development of an immunosuppressive microenvironment, leading to the inhibition of proper immune functioning and suppression of the immunoblast response, which prevents the immune system from detecting and attacking tumor cells.
• Resistance to standard therapy: As it has been stated above, traditional methods, including chemotherapy and radiotherapy, cannot be used to provide long-term control. Recurrence rates are high with the usage of even the aggressive regimens, and advanced pancreatic cancer is often found to be refractory to subsequent treatment.

Moreover, pancreatic cancer cells are genetically diverse – therefore, they become less amenable to one-size-fits-all therapy. Consequently, alternative treatment approaches, especially those that reinitiate the immune system through special therapy, are needed to enhance the results of pancreatic cancer treatment.

Modulation of antitumor immunity: algorithm of personalized vaccination

Unlike conventional vaccines, which prevent the disease, vaccine therapy for pancreatic cancer is therapeutic. This is a treatment method that "teaches" the patient's own immune system to recognize and destroy existing cancer cells. This immunotherapy uses dendritic cells, which were discovered by Canadian immunologist Ralph Steinman, who was awarded the Nobel Prize in Physiology or Medicine [6]. To activate tumor recognition by the immune system, patients are prescribed an individual cancer vaccine. Pancreatic cancer often remains "invisible" to the body's own protective cells, making such immunological care critical.

Dendritic cells perform the function of the main presenters of antigens in the body, which directly determines the evolving role of dendritic cells in cancer therapy as one of the most promising directions of modern immuno-oncology. Their task is not to directly destroy the tumor, but to professionally train the immune system. They capture specific proteins of cancer cells, process them, and "demonstrate" to T-lymphocytes (T-killer cells). In this way, the immune system receives the exact coordinates of the "enemy" and a clear order to launch an attack.

Pancreatic cancer is known for its ability to create a powerful immunosuppressive barrier. Creating a vaccine against pancreatic cancer allows immunity to bypass this obstacle, thanks to the following factors:

• High pointing accuracy. Vaccination adjusts the body's immune response exclusively to the recognition of specific antigens of cancer. Pancreatic vaccine works selectively, which minimizes damage to healthy tissues and makes such treatment much safer than standard chemotherapy.
• Activation of immunity outside the tumor. Since dendritic cells are prepared in a specialized laboratory, the tumor cannot suppress their activity at the "learning stage".
• Systemic control over metastases. Trained immune cells circulate throughout the body, finding and destroying even the smallest pockets of disease that cannot be seen on CT or MRI.
• Creating immune memory. After completing the course, the body stores information about tumor proteins, which helps prevent relapses in the long term.

There are main mediators that ensure the initiation and coordination of specific immune reactions in the body. They are dendritic cells. Pancreatic cancer Germany programs contain such methods, where these cells are used. They take antigens from pancreatic cancer and present them to T-cells, which then recognize and kill tumor cells – even the most difficult-to-target ones. This therapy allows the immune system to eliminate cancer cells more effectively and reduce the damage to healthy tissues by generating cytotoxic lymphocytes that attack these malignant cells.

Unfortunately, pancreatic adenocarcinoma is the most stubborn cancer type with respect to immunotherapy. Its immunosuppressive microenvironment and thick stroma form an opaque barrier, resulting in abnormally low concentrations of active dendritic cells. Research has also demonstrated that pancreatic cancer tumors can harbor up to 80 times fewer dendritic cells than other responsive cancers, such as lung or gastric cancer. The available dendritic cells are also underdeveloped and incapable of activating T-cells [5].

To overcome this immunological barrier, a new vaccine for pancreatic cancer treatment is used, in which the patient's own monocytes are transformed into laboratory-cultured dendritic cells. These cells are then "trained" using pancreatic cancer antigens derived from pancreatic cancer cells and reintroduced into the body as a therapeutic cancer vaccine. This personalized approach helps boost the natural immune response against pancreatic cancer cells, providing patients with a new and promising strategy to fight advanced pancreatic cancer.

The dendritic cell vaccine:

• Educates T-cells to recognize and destroy pancreatic cancer cells
• Stimulates a tumor-specific immune response
• Enhances the immunogenicity of resistant tumor cells
• Functions as a low-toxicity, highly targeted cancer treatment

Outcomes of Dendritic Cell Therapy for Pancreatic Cancer

Despite the historically poor outcomes associated with pancreatic ductal adenocarcinoma, recent studies have demonstrated that dendritic cell vaccination offers significant benefits for metastatic pancreatic cancer. These studies show that treatment-induced immune responses can significantly prolong survival – even in patients with advanced stages and those with metastatic disease. 

This approach is of particular importance as stage 3 dendritic cell immunotherapy for pancreatic cancer treatment. Germany is the leading state where such immunological control protocols allow stabilization of the condition even in cases that were previously considered incurable.

Clinical data indicate a powerful synergistic effect demonstrated by the new vaccine. Pancreatic cancer responds much better to treatment thanks to the combination of immunotherapy with standard chemotherapy. For patients with stage IV, the main goal is not complete regression, but the transfer of the aggressive process into a controlled chronic form. DC therapy contributes to long-term stabilization of tumor size and inhibition of the appearance of new metastatic foci [10].

In the late stages, when surgical intervention is usually impossible, and the tumor has multiple metastases (most often in the liver or peritoneum), the vaccine for pancreatic cancer treatment acts as an adjuvant (additional) method.

LANEX-DC® Study – Germany

A retrospective study in 16 patients with gastrointestinal tumours (gastric and pancreatic cancer) following surgical resection demonstrated a significant improvement in survival rates through the usage of dendritic cell therapy. Germany is the main platform for the implementation of the LANEX-DC® protocol, which allows achieving stable results in complex clinical cases [7].

Results showed:

• 5-year disease-free survival (DFS): 62.5%
• 5-year overall survival (OS): 67.5%
• No serious side effects reported
• Some recurrences occurred after 7 years, indicating long-term immune memory

The therapy was well tolerated, reinforcing the dendritic cell vaccine as a safe approach in adjuvant therapy for patients with pancreatic cancer.

REACtiVe Study – Netherlands

This phase I study explored the safety and efficacy of allogeneic tumor lysate-loaded dendritic cells in resected pancreatic cancer patients [8].

Main results:

• All patients developed activated PD-1+ and Ki67+ T cells.
• Immune responses were confirmed in blood, skin, and tumor tissue.
• 7 out of 10 patients remained recurrence-free at 25 months (median follow-up)
• Clinical data confirm the absence of serious adverse reactions directly related to the administration of the individual vaccine. Pancreatic cancer with this approach is treated without systemic toxicity.

These findings underscore the dendritic cell vaccine’s potential to generate durable immune responses and delay recurrence in pancreatic cancer patients.

DC-CIK + S-1 Chemotherapy Study – Asia

In patients with advanced pancreatic cancer, a combination of dendritic cells, cytokine-induced killer (CIK) cells, and S-1 chemotherapy showed [9]:

• Median overall survival: 212 days
• Progression-free survival: 136 days
• Improved immune function (e.g., CD4+, CD8+/CD28+ T-cell subsets)
• Reduced tumor cell DNA in the bloodstream
• No grade 3-4 toxicities observed

These results demonstrate that treatment of advanced pancreatic cancer with dendritic cells can extend life, enhance immune responses, and provide hope for patients with pancreatic cancer who face limited options.

There are different treatment approaches in global practice, which is due to the structure of health systems and the speed of implementation of innovative vaccine therapy. Pancreatic cancer needs access to state-of-the-art protocols, the availability of which in different countries depends on the level of development of medical technologies and the availability of innovations.

Below is a comparative analysis of care in leading countries with an emphasis on the benefits of treatment in Germany.

Comparative review of dendritic cell therapy in different countries

How Dendritic Cell Therapy Is Performed in Pancreatic Cancer

Dendritic cell therapy is a form of treatment that is highly customized for the treatment of pancreatic cancer. It involves the usage of the patient`s immune system to attack cancer cells. In contrast to traditional treatments, which are systemic and usually damage normal tissues, the therapy is based on the autologous cells, producing a specific immune response. All processes occur in sterile and GMP-approved laboratories, with safety and reproducibility being ensured without breaking the strict rules of regulation.

Step 1: Blood Collection and Cell Isolation

The treatment commences by taking about 200 ml of blood from the patient who has pancreatic cancer. Different categories of immune cells, such as monocytes that form the precursors of dendritic cells, can be found in this sample. The blood is processed under rigidly controlled circumstances to maintain cells in their optimal condition. Centrifugation separates the components of the blood: red blood cells, granulocytes (nonspecific immune cells), and a lymphocyte-rich portion is isolated. This fraction contains the patient-specific cells that will undergo the process of generating the mature dendritic cells that will subsequently be trained to identify the cells of pancreatic cancer.

Step 2: Culturing and Priming of Antigens

The separated precursor cells are placed in culture enriched in nutrients and certain growth factors that support their survival and proliferation. Autologous tumor antigens that have been isolated from the plasma or tumor tissue of the patient are now added to prime the cultured cells. This has the effect of training the dendritic cells to present the tumor-specific markers to T-cells. These cells are now matured over a period of 7 days by means of the addition of growth factors that induce them to take the characteristic dendritic morphology, increased surface area, and enhanced capacity to communicate with immune cells. They are carefully studied as to morphology, viability, and functional competence during this period to ensure that the desired immune response will be obtained.

Step 3: Quality Control and Preparation of Vaccines

Rigorous quality control is done on the seventh day of the culture. Flow cytometry is employed to establish the existence of important surface markers, the total number of cells, and overall viability. Only the cells of high quality are made ready for administration. The resulting dendritic cells are then loaded into the syringe as a vaccine treatment for pancreatic cancer, which is prepared to be reintroduced into the patient. Through this planning, every patient is guaranteed a good therapeutic product of high quality that can activate their immune system without unnecessary toxicity.

Step 4: Administration and Recovery

The dendritic cell vaccine is injected directly under the skin, either in the groin or the upper arms, where the dendritic cells are able to communicate with the immune system of the body. After the injection, supportive treatments are often provided to enhance its effectiveness and the recovery of the patient's immune function. Most patients can return home on the same day. Once administered, the dendritic cells present tumor antigens to T-cells so that they are aware of the tumor cells and are able to destroy them. This expands the immune response, as well as shows great specificity in the treatment of patients with advanced pancreatic cancer, with a better long-term survival.

Clinical and Biological Significance

Dendritic cell therapy is an example of the level of accuracy and customization that can be provided in immunotherapy for pancreatic cancer. The therapy aims to minimize systemic side effects by utilizing the cells of the patient and individual tumor antigens, coordinating the immune response. The protocol is especially useful for patients with pancreatic cancer who sometimes lack helpful alternatives because of tumor location, dense stroma, or resistance to chemotherapy and radiation. Additionally, this practice helps in the formation of immune memory, allowing the patient’s immune system to find the cancer cells in the pancreas and destroy them months or years after treatment.

Treatment of Pancreatic Cancer without Aggressive Toxicity: Advantages of Immunotherapy

Although conventional chemotherapy continues to be one of the most widespread first-line treatment options in pancreatic cancer, it is mostly constrained by adverse effects, resistance, and damage to healthy tissue. In contrast to cytostatic therapy, a safe immune enhancement and targeted effects on tumor antigens are provided by a personalized dendritic cell vaccine. Pancreatic cancer Germany programs include options of treatment, where such vaccines are used. It allows to activate the body's defenses without aggressive effects on normal cells.

Distinctions to Chemotherapy

• Activation of the immune system against specific targets vs. non-specific cytotoxic activation
• Little side effects compared to nausea, fatigue, and immune suppression
• Specific immunity against cancer and local tumor immunity
• Repeatable and has non-cumulative toxicity with other treatments used in the treatment of pancreatic cancer

This makes dendritic cell therapy a very attractive alternative to conventional chemotherapy for patients with advanced pancreatic cancer who cannot tolerate more aggressive systemic therapies, or for individuals who prefer less harmful therapy with long-term benefits.

Advantages of Combination and Integrative Cancer Care

• Multimodal oncology
• Enhanced tumor detection and tumor cell destruction
• Enhanced immune reactions and decreased relapses
• Fits in with integrative cancer care models (e.g., nutritional and lifestyle support)

Therefore, dendritic cell vaccination can be used not only independently but also in combination therapy, which aligns with modern, patient-centered approaches and gives hope to patients with pancreatic cancer.

Advantages of an Approach Using Radiation Therapy and Immunostimulation

Traditionally, radiation therapy has shown limited effectiveness in treating pancreatic cancer tumors due to the disease’s immunosuppressive microenvironment. Although radiation therapy damages tumor cells, it often fails to trigger a strong enough response from the immune system to prevent recurrence.

Nonetheless, with current developments in the field of cancer immunotherapy, this is no longer the case, as discussed earlier. Radiation can be used as an immune activator when combined with dendritic cell therapy. When radiation destroys cancer cells in the pancreas, the tumor antigens are introduced into the blood, and this is where dendritic cells come in.

How the combination works:

• Radiation treatment causes immunogenic cell death and antigen release
• Dendritic cells take these antigens and present them to T-cells
• This causes systemic activation of the immune system, not just local tumor control
• It improves the efficacy of radiation with a decrease in collateral damage

This method transforms radiation as a localized treatment into an impulse for whole-body cancer treatment, producing enhanced results even in otherwise incurable pancreatic adenocarcinoma.

The sequencing of radiation and DC vaccination is the variable that determines whether this combination amplifies or undermines the immune response. Radiation administered too close to vaccination can damage the circulating immune cells that the vaccine has just activated; administered at the right interval before vaccination, it releases the tumor antigens that give the dendritic cells their most current and accurate targeting information. Booking Health's combination therapy sequencing review confirms that the proposed protocol at the candidate German center reflects the timing conditions under which the synergistic effect the comparison table describes is actually achieved.

In order for you to objectively assess the possibilities of each approach, we have prepared a comparative table. It demonstrates exactly how the combination of methods allows to level the shortcomings of each of them separately and achieve a synergistic effect, transforming the local effect on the body's systemic response.

Choosing the optimal treatment strategy to achieve the maximum result

Why is the combination more justified? This turns passive treatment into an active process where the patient's immunity begins to independently recognize and attack even those cells that are outside the radiation zone.

Professor Frank Gansauge reveals the benefits of immunotherapy for pancreatic cancer patients

One of the most respected experts in dendritic cell-based cancer immunotherapy is Professor Frank Gansauge, founder of LDG Laboratories in Berg, Germany. A surgeon by education but an immunologist at heart, Prof. Dr. Gansauge has been among the leaders of dendritic cell therapy for over two decades, helping shape what is now one of the most innovative approaches in pancreatic cancer treatment and beyond.

"I call dendritic cells the 'officers' of the immune system," he explains. "They train the immune cells – the effector T-cells – to recognize and eliminate cancer cells."

One of the earliest in Europe to use EU GMP standards on autologous dendritic cell therapy was Prof. Dr. Gansauge, as early as 2001. His focus is on a patient-centered approach, which involves incorporating conventional methods of treating a patient, such as chemotherapy and radiation therapy, along with individualized treatment through immunotherapy in a home-like environment.

His team has invented the LANEX-DC protocol, which has proven to decrease relapse rates in gastrointestinal cancers, such as gastric cancer and pancreatic cancer, and also increase life expectancy, at least in some cases, achieving complete tumor remission. Within the framework of integrative anticancer therapy, he often recommends an individual approach to the fight against cancer. Vaccine for pancreatic cancer in this format involves using only one fresh batch of cells instead of a series of injections, as one dendritic cell is able to train an entire group of lymphocytes, and the antigenic profile of the tumor has the property of transforming over time.

"We aim not only to restore physical health but also a patient's mental well-being."

Another area that Prof. Dr. Gansauge finds exciting is anti-aging medicine, where patients report that they look younger and feel more vital after undergoing immunotherapy for pancreatic cancer yearly.

To learn more about the philosophy of Prof. Dr. Gansauge, his clinical experience, and the science of dendritic cell therapy, we strongly suggest watching his entire interview. In this discourse, he describes the mechanism of action of the dendritic cells, the process of therapy, the reason some cases of pancreatic cancer patients have long-term remission, and how this form of treatment has been extended to other fields, such as the treatment of chronic infections and research on longevity.

The best medical centers in Germany with experience in the use of dendritic cell vaccines

Germany provides access to some of the world's most advanced immunotherapy for pancreatic cancer, offering personalized care for patients with pancreatic cancer and other hard-to-treat malignancies. These specialized hospitals are known for combining innovative techniques with high safety standards and international treatment protocols.

Top German cancer centers offering dendritic cell therapy:

LDG – Laboratories Dr. Gansauge (Berg)

Led by Professor Frank Gansauge, this medical center specializes exclusively in the development and application of dendritic cell therapy. The laboratory has over 22 years of experience in the field of immunology. The basis of treatment is the author's LANEX-DC® protocol. For patients with pancreatic cancer, dendritic cells are grown from the patient's own blood monocytes. In laboratory conditions, cells undergo a maturation step and are activated by specific tumor antigens. This allows for getting the most active immune product ready to recognize adenocarcinoma immediately after introduction into the body.

Advantages and differences

• Narrow specialization and a huge clinical database on patient survival
• Use of a standardized protocol with high reproducibility of results
• The possibility of therapy both in the adjuvant mode (after surgery) and in palliative treatment

IOZK – Immuno-Oncology Center (Cologne)

The Center for Immuno-Oncology in Cologne is known for its comprehensive approach to activating the immune system. IOZK specialists consider the tumor as a dynamic system that requires multi-stage exposure. Here, the IO-VAC strategy is applied, combining dendritic cell vaccine administration with oncolytic viruses and local hyperthermia. Pancreatic cancer initially uses virotherapy to destroy the protective barrier of the tumor. This releases tumor proteins, which are then more easily recognized by the vaccine's dendritic cells, greatly enhancing the overall therapeutic effect.

Advantages and differences

• Multimodal strategy (viruses + hyperthermia + vaccine)
• Deep personalization of the program based on the patient's immunological profile
• Works closely with international patients with pancreatic cancer seeking treatment in Germany

Praxisgemeinschaft für Zelltherapie (Duderstadt)

The team of doctors in Duderstadt focuses on individual solutions in the field of regenerative and immune medicine, using many years of experience in cell therapy. The Centre offers adapted immunization protocols. For the treatment of pancreatic cancer, doctors carry out a thorough selection of tumor markers that will be presented to dendritic cells. Special attention is paid to the creation of long-term immune memory to prevent metastasis and recurrence of the disease after the completion of the main course.

Advantages and differences

• A multidisciplinary approach involving doctors of various specialties
• High level of clinical safety and personalized support
• Flexibility in combining cell therapy with other methods of supporting the body

These German cancer centers represent the most advanced field of cancer therapy, offering innovative options to patients with pancreatic cancer seeking effective, science-supported alternatives to conventional treatment.

The production of a vaccine for pancreatic cancer in Germany follows a clear algorithm that ensures the highest quality of biological material.

The cost of pancreatic cancer treatment and the main stages of medical care

Dendritic cell immunotherapy of pancreatic cancer in Germany for patients with advanced pancreatic cancer costs between 20,000 and 38,000 EUR, depending on the clinic, type of procedure, and whether the treatment is combined with other pancreatic cancer therapies.

The length of stay of patients suffering from pancreatic cancer varies based on the type of cancer and the treatment applied to them. Therefore, a time span of 7 to 14 days is considered sufficient to include medical check-ups, blood tests, vaccine preparation, and administration of the final cancer therapy. A majority of the clinics also include after-treatment follow-up and nutritional support, which guarantees maximum immune functioning and control of immune responses.

The German medical system offers exceptionally high standards and advanced laboratories to combat pancreatic cancer. Patients get access to highly specialized and safe treatment, the cost of which may vary depending on the individual characteristics and complexity of the clinical case. This multifaceted strategy improves the efficacy of cancer immunotherapy, as well as the immune response, to eliminate tumor cells and treat advanced pancreatic cancer.

When evaluating the possibilities of targeted immunotherapy for aggressive tumors, such as pancreatic, vaccine for cancer must be considered not only through medical indicators but also through the economic availability and legal status of the method in different countries. The cost of immunotherapy varies significantly depending on the structure of the health care system, the level of state regulation of laboratory processes, and the costs of developing an individual drug. Below is a detailed comparative overview of the financial and organizational features of dendritic cell therapy. Pancreatic cancer Germany programs provide the availability and effectiveness of this method in the leading medical centers.

Comparative cost and availability of immunotherapy with dendritic cells in different countries of the world

Pancreatic Cancer Patient Experience: Robert Franklin Smith

Robert Franklin Smith was diagnosed with advanced pancreatic cancer, which had spread to the liver. He went through surgery and chemotherapy in the United States and then went to foreign countries to explore other options.

Booking Health enabled his family to learn about pancreatic cancer treatment in Germany and connect with LDG Laboratories, where he underwent dendritic cell-based immunotherapy against pancreatic cancer under the supervision of leading experts. His wife said it was a life-changing experience, not only because of the treatment itself but also due to the kindness and professionalism of the entire medical team.

She emphasized the seamless organization, effective communication, and the comfort the process provided. To Robert, the treatment offered not only a medical option but also restored hope, a stronger immune system, and quality time with his family, which demonstrates the tangible effect of cancer immunotherapy on patients with advanced pancreatic cancer.

Stages of Organization and Implementation of Dendritic Cell Therapy in German Clinics

Collaboration with Booking Health allows patients to focus on recovery, passing all organizational and logistical issues to professionals. The process is structured as a clear sequence of actions to ensure access to the best German medical standards.

It is important to understand that clinical protocols can differ significantly depending on the chosen medical institution and the specifics of the oncological process. Each clinic adapts the scheme of administration of drugs and accompanying therapy to the individual needs of the patient.

During the first visit, the doctor examines the medical history in detail and discusses all available treatment options with the patient. At this stage, special attention is paid to the integrative approach of correcting the diet and selecting nutritional support to strengthen the immune response.

Usually, the next day, a venous blood collection procedure (about 150-200 ml) is performed, which is safe and does not require nutritional restrictions. For "preparation" of the immune system, the patient is prescribed infusions of B-group vitamins and vitamin C. A key element is the stimulation of natural killer cells (NK cells) through intramuscular administration of a high dose of vitamin D (50,000 IU).

During the next week, the process of maturation of dendritic cells and their "training" to recognize tumor antigens takes place in a specialized laboratory. The patient can be under supervision or rest at this time.

On the 9th day, the main procedure, intradermal administration of the vaccine, is performed. Vitamin infusions and another stimulating injection of vitamin D (50,000 IU) are repeated to consolidate the result.

Once the active phase is complete, the patient is prescribed a home regimen of vitamin D, 40,000 IU per week, orally. This is necessary to maintain the high activity of immune cells that have been "trained" by the vaccine.

A Medical Journey: Every Step of the Way With Booking Health

Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.

Our team consists of a group of specialized doctors who have more than 15 years of practical experience in the field of medical tourism. We have combined medical expertise with impeccable organization to ensure patients have access to the best global technology.

Over the years, we have processed hundreds of thousands of applications from patients from all over the world. Behind each of these numbers are saved lives and direct contacts with leading cancer centers, which allows us to act quickly and efficiently.

To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex management programs in each individual case. As a reputable company, Booking Health offers personalized treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment.

We provide:

• Assessment and analysis of medical reports
• Development of the medical care program
• Selection of a suitable treatment location
• Preparation of medical documents and forwarding to a suitable clinic
• Preparatory consultations with clinicians for the development of medical care programs
• Expert advice during the hospital stay
• Follow-up care after the patient returns to their native country after completing the medical care program
• Taking care of formalities as part of the preparation for the medical care program
• Coordination and organization of the patient's stay in a foreign country
• Assistance with visas and tickets
• A personal coordinator and interpreter with 24/7 support
• Transparent budgeting with no hidden costs

 

We understand the needs of patients and offer conditions that make complex treatment abroad understandable, accessible, and safe.

Advantage	What does it mean for you
Budget economy	Reduction of treatment costs from 40% to 70% thanks to process optimization
Fixed cost	The price of treatment remains unchanged, which excludes unexpected financial costs
Large-scale experience	More than 10 years of specialization in medical tourism and 15 years of medical practice
Modern clinics	Direct contracts exclusively with accredited and the best cancer centers in the world
Urgency	Organization of access to treatment and hospitalization within 48 hours

Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods and with leading specialists in this field.

Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.

Get a tailored treatment strategy for my case

Practical achievements of Booking Health in the field of individual treatment with dendritic cells

Tommy G. (Ireland), April 2026

Sarah M. (United Kingdom), April 2026

Diane O. (United Kingdom), March 2026

Faeqa M. (Bahrain), March 2026

Helen G. (United Kingdom), February 2026

Jared Todd M. (USA), February 2026

Emmanuel K. (USA), January 2026

Peter H. (United Kingdom), January 2026

Patrick D. (Ireland), December 2025

Ronald C. (Canada), November 2025

Monica A. (Croatia), October 2025

Robert B. (USA), September 2025

David D. (United Kingdom), September 2025

Sargon B. (USA), August 2025

Amanda Louise C. (Australia), July 2025

Contact Our Team to Request Dendritic Cell Therapy for Pancreatic Cancer

Authors:

This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Daria Sukhoruchenko. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!

Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.

Sources:

01. Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. Author manuscript; available in PMC: 2022 Aug 9. Published in final edited form as: JAMA. 2021 Sep 7;326(9):851–862. doi: 10.1001/jama.2021.13027. [DOI] [PubMed] [PMC free article]

02. R van ‘t Land F, Willemsen M et al. Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol. 2024 Jul 1;42(26):3083–3093. doi: 10.1200/JCO.23.02585. [DOI] [PubMed] [PMC free article]

03. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 [DOI] [PubMed] [PMC free article]

04. Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017 Jun 22;18(7):1338. doi: 10.3390/ijms18071338. [DOI] [PubMed] [PMC free article]

05. Deicher A, Andersson R, Tingstedt B et al. Targeting dendritic cells in pancreatic ductal adenocarcinoma. Cancer Cell Int. 2018 Jun 18;18:85. doi: 10.1186/s12935-018-0585-0. [DOI] [PubMed] [PMC free article]

06. Alla Katsnelson; Kicking off adaptive immunity: the discovery of dendritic cells. J Exp Med 10 July 2006; 203 (7): 1622. doi: 10.1084/jem.2037fta. [DOI]

07. Gansauge F, Poch B. Evaluation of long antigen exposition dendritic cell therapy (LANEX-DC®) in the adjuvant treatment of pancreatic cancer – results of a single center analysis. July 2022. Archives of Cancer Science and Therapy. 6(1):006-008. [DOI]

08. Lau SP, Klaase L et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. European Journal of Cancer, 2022; 169, 20-31. [DOI]

09. Ni Jiang, Guoliang Qiaoet al. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res 1 September 2017; 23 (17): 5066–5073. doi: 10.1158/1078-0432.CCR-17-0492. [DOI]

10. Somasundaram A, Yeh JJ. Future of Dendritic Cell-based Approaches in Pancreatic Cancer. J Clin Oncol. Author manuscript; available in PMC: 2025 Sep 10. Published in final edited form as: J Clin Oncol. 2024 Jul 11;42(26):3067–3070. doi: 10.1200/JCO.24.00846. [DOI] [PubMed] [PMC free article]

Read:

01. Evolving Standards of Care for Pancreatic Cancer in Germany

02. Treatment of stage 4 pancreatic cancer in Germany

03. Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany